Abstract:The non-dystrophic myotonias are an important group of skeletal muscle channelopathies electrophysiologically characterized by altered membrane excitability. Many distinct clinical phenotypes are now recognized and range in severity from severe neonatal myotonia with respiratory compromise through to milder late-onset myotonic muscle stiffness. Specific genetic mutations in the major skeletal muscle voltage gated chloride channel gene and in the voltage gated sodium channel gene are causative in most patients. Recent work has allowed more precise correlations between the genotype and the electrophysiological and clinical phenotype. The majority of patients with myotonia have either a primary or secondary loss of membrane chloride conductance predicted to result in reduction of the resting membrane potential. Causative mutations in the sodium channel gene result in an abnormal gain of sodium channel function that may show marked temperature dependence. Despite significant advances in the clinical, genetic and molecular pathophysiological understanding of these disorders, which we review here, there are important unresolved issues we address: (i) recent work suggests that specialized clinical neurophysiology can identify channel specific patterns and aid genetic diagnosis in many cases however, it is not yet clear if such techniques can be refined to predict the causative gene in all cases or even predict the precise genotype; (ii) although clinical experience indicates these patients can have significant progressive morbidity, the detailed natural history and determinants of morbidity have not been specifically studied in a prospective fashion; (iii) some patients develop myopathy, but its frequency, severity and possible response to treatment remains undetermined, furthermore, the pathophysiogical link between ion channel dysfunction and muscle degeneration is unknown; (iv) there is currently insufficient clinical trial evidence to recommend a standard treatment. Limited data suggest that sodium channel blocking agents have some efficacy. However, establishing the effectiveness of a therapy requires completion of multi-centre randomized controlled trials employing accurate outcome measures including reliable quantitation of myotonia. More specific pharmacological approaches are required and could include those which might preferentially reduce persistent muscle sodium currents or enhance the conductance of mutant chloride channels. Alternative strategies may be directed at preventing premature mutant channel degradation or correcting the mis-targeting of the mutant channels.

Classification of Involuntary Movements in Dogs: Myoclonus and Myotonia

Clinical analysis and gene mutation screening of CLCN1 in two myotonia congenita families

Novel chloride channel gene mutations in two unrelated Chinese families with myotonia congenita.

Dystonia in veterinary neurology

Clinical Utility of Neurophysiologic Classification (and Declassification) of Myoclonus

International veterinary canine dyskinesia task force ECVN consensus statement: Terminology and classification

Myoclonus and other jerky movement disorders

Myoclonus: an update

New Classification and Treatment for Myotonic Disorders

The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment

The diagnosis and treatment of myotonic disorders

Gaps and Controversies in Catatonia as a Movement Disorder

Myotonic Disorders in Childhood: Diagnosis and Treatment

A novel mutation of the CLCN1 gene in a cat with myotonia congenita: Diagnosis and treatment

[Myokymia]

Current Classification of Canine Muscular Dystrophies and Identification of New Variants

Neuromyotonia

Guidelines on clinical presentation and management of nondystrophic myotonias

Canine paroxysmal dyskinesia-a review

Diagnosis and treatment of functional myoclonus